Clara Campas Moya
Managing Partner and co-founder @ Asabys Partners
Barcelona, Spain
Clara Campas Moya is a seed investor at Asabys Partners in Barcelona focused on Biotechnology and Pharmaceutical. Clara Campas Moya is based out of Barcelona, Catalonia and is the Managing Partner and co-founder of Asabys Partners. Clara previously worked at Kern Pharma as a Strategy & Development Director. Clara Campas Moya attended the University of Barcelona.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries Clara Campas Moya invests in
Stages Clara Campas Moya invests in
Countries Clara Campas Moya invests in
Investment Focus
Industry
- Biotechnology 5 (45%)
- Pharmaceutical 3 (27%)
- Biopharma 2 (18%)
- Health Care 2 (18%)
- Life Science 2 (18%)
Stage
- Seed 3 (27%)
- Series A 2 (18%)
- Series B 2 (18%)
- Pre-Seed 1 (9%)
- Series D 1 (9%)
Country
- Spain 4 (36%)
- Belgium 2 (18%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ona Therapeutics
|
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $86.6M / Series B / Jun 04, 2026 | |
Oriva Therapeutics
|
Oriva Therapeutics is a women's health company that treats chronic conditions affecting women. | Pre-Seed / Jan 22, 2026 | |
|
Ona Therapeutics
|
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $11.6M / Venture - Series Unknown / Oct 09, 2025 | |
Augustine Therapeutics
|
Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M / Series A / Mar 24, 2025 | |
AgomAb Therapeutics
|
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $88.7M / Series D / Oct 25, 2024 | |
|
Augustine Therapeutics
|
Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $18.2M / Series A / Jun 26, 2024 | |
Nuage Therapeutics
|
Nuage Therapeutics is a pharmaceutical company which utilizes chemical biology and biomolecular condensation to develop selective drugs that target proteins with disordered regions for challenging indications to improve patient’s life. The focus of the medication is to enhance selective inhibitors of intrinsically disordered proteins involved inchallenging indications in order to meet unmet medical needs. | $12.9M / Seed / Mar 14, 2023 | |
|
AgomAb Therapeutics
|
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $38.5M / Series B / Jul 13, 2022 | |
Origo Biopharma
|
Origo Biopharma is a biotech company, specializes in research and development of immunotherapeutic products that address health disorders related to TGF-β signaling dysfunction, among this cancer and fibrosis. | $2.5M / Seed / Jul 07, 2020 | |
|
Ona Therapeutics
|
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $33.8M / Series A / Jun 16, 2020 | |
| See all 11 investments → | |||
Co-Investors
Fund+
4 deals together
Alta Life Sciences
3 deals together
Ysios Capital
3 deals together
Bpifrance
2 deals together
CDTI Innovación's INNVIERTE program
2 deals together
CMT Research Foundation
2 deals together
About Asabys Partners
Asabys Partners is a venture capital firm that invests across the board in human healthcare. The company is active in the health-tech and biopharma industries and aims to invest in Spain and abroad in innovative and transformative technologies. Asabys Partners are motivated by the idea of pushing the boundaries of science and medicine. This is donethrough the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry.
Asabys Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Clara Campas Moya
Managing Partner and co-founder
|
|||
Montserrat Vendrell
Partner
|
|||
Nuria Aloy
CFO
|
|||
Josep Sanfeliu
Managing Partner and Co-Founder
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Clara Campas Moya invest in?
Clara Campas Moya invests primarily in Biotechnology, Pharmaceutical and Biopharma startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Clara Campas Moya last invest?
The most recent investment recorded for Clara Campas Moya closed in Jun 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
